KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $126.3 million.

  • Jazz Pharmaceuticals' Change in Accured Expenses rose 14748.55% to $126.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.7 million, marking a year-over-year decrease of 2630.29%. This contributed to the annual value of $86.2 million for FY2024, which is 47065.61% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Change in Accured Expenses stood at $126.3 million, which was up 14748.55% from -$256.4 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Change in Accured Expenses registered a high of $181.0 million during Q1 2025, and its lowest value of -$256.4 million during Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' median Change in Accured Expenses value was $34.7 million (recorded in 2024), while the average stood at $22.2 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 72221.58% in 2021, then plummeted by 77585.49% in 2025.
  • Jazz Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $48.8 million in 2021, then surged by 203.41% to $148.1 million in 2022, then tumbled by 64.21% to $53.0 million in 2023, then plummeted by 43.92% to $29.7 million in 2024, then skyrocketed by 324.73% to $126.3 million in 2025.
  • Its last three reported values are $126.3 million in Q3 2025, -$256.4 million for Q2 2025, and $181.0 million during Q1 2025.